MYC as therapeutic target for embryonal tumors: Potential and challenges

Current Cancer Drug Targets

Volumn 16, Issue 1, 2016, Pages 2-21

  Shalaby, Tarek ^a   Grotzer, Michael A ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

Embryonal tumors; Medulloblastoma; MYC; Neuroblastoma; Pediatric cancer

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ALISERTIB; CASPASE 8; DEXTRO LACTATE DEHYDROGENASE; DINACICLIB; FLAVOPIRIDOL; FOSTAMATINIB; GLUTAMINASE; IBRUTINIB; MYC PROTEIN; N2 [2 (3,5 DIFLUOROPHENYL) 2 HYDROXYACETYL] N1 (6,7 DIHYDRO 5 METHYL 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL)ALANINAMIDE; NUTLIN 3; ORNITHINE DECARBOXYLASE; PURVALANOL A;

ARTICLE; CANCER THERAPY; CELL PROLIFERATION; CELL VIABILITY; CLINICAL TRIAL (TOPIC); COLONY FORMATION; DOWN REGULATION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HUMAN; MEDULLOBLASTOMA; MOLECULAR GENETICS; NEUROBLASTOMA; NONHUMAN; ONCOGENE MYC; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN STABILITY; ANIMAL; DISEASE MODEL; GENE THERAPY; GENETICS; MOUSE; NEOPLASMS, GERM CELL AND EMBRYONAL;

ANIMALS; DISEASE MODELS, ANIMAL; GENES, MYC; GENETIC THERAPY; HUMANS; MICE; NEOPLASMS, GERM CELL AND EMBRYONAL;

EID: 84953742368     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009615666150916092745     Document Type: Article

References (252)

1. Nesbit, C. E.; Tersak, J. M.; Prochownik, E. V. MYC oncogenes and human neoplastic disease. Oncogene, 1999, 18(19), 3004-3016
2. DePinho, R. A. The age of cancer. Nature, 2000, 408 (6809), 248-254
3. Eilers, M.; Eisenman, R. N. Myc's broad reach. Genes Dev., 2008, 22(20), 2755-2766.
4. Adhikary, S.; Eilers, M. Transcriptional regulation and transformation by Myc proteins. Nat. Rev. Mol. Cell Biol., 2005, 6(8), 635-645.
5. Fernandez, P. C.; Frank, S. R.; Wang, L.; Schroeder, M.; Liu, S.; Greene, J.; Cocito, A.; Amati, B. Genomic targets of the human c-Myc protein. Genes Dev., 2003, 17(9), 1115-1129
6. Li, Z.; Van Calcar, S.; Qu, C.; Cavenee, W. K.; Zhang, M. Q.; Ren, B. A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc. Natl. Acad. Sci. USA, 2003, 100(14), 8164-9.
7. Schuhmacher, M.; Kohlhuber, F.; Holzel, M.; Kaiser, C.; Burtscher, H.; Jarsch, M.; Bornkamm, G. W.; Laux, G.; Polack, A.; Weidle, U. H.; Eick, D. The transcriptional program of a human B cell line in response to Myc. Nucleic Acids Res., 2001, 29(2), 397-406.
8. Gartel, A. L.; Ye, X.; Goufman, E.; Shianov, P.; Hay, N.; Najmabadi, F.; Tyner, A. L. Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proc. Natl. Acad. Sci. USA, 2001, 98(8), 4510-4515.
9. de Nigris, F.; Botti, C.; Rossiello, R.; Crimi, E.; Sica, V.; Napoli, C. Cooperation between Myc and YY1 provides novel silencing transcriptional targets of alpha3beta1-integrin in tumour cells. Oncogene, 2007, 26(3), 382-394.
10. Sabo, A.; Kress, T. R.; Pelizzola, M.; de Pretis, S.; Gorski, M. M.; Tesi, A.; Morelli, M. J.; Bora, P.; Doni, M.; Verrecchia, A.; Tonelli, C.; Faga, G.; Bianchi, V.; Ronchi, A.; Low, D.; Muller, H.; Guccione, E.; Campaner, S.; Amati, B. Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis. Nature, 2005, 511(7510), 488-492.
11. Horiuchi, D.; Anderton, B.; Goga, A., Taking on challenging targets: making MYC druggable. Am Soc Clin Oncol Educ Book 2014, e497-502
12. Wade, M.; Wahl, G. M., c-Myc, genome instability, and tumorigenesis: the devil is in the details. Curr. Top Microbiol. Immunol., 2006, 302, 169-203.
13. Dang, C. V.; O'Donnell K, A.; Juopperi, T. The great MYC escape in tumorigenesis. Cancer Cell. 2005, 8(3), 177-178.
14. Jennings, M. T.; Pietenpol, J. A. The role of transforming growth factor beta in glioma progression. J. Neuro-Oncol., 1998, 36, 123-140.
15. Liao, D. J.; Dickson, R. B. c-Myc in breast cancer. Endocr. Relat. Cancer, 2000, 7(3), 143-164.
16. Wu, R.; Lin, L.; Beer, D. G.; Ellenson, L. H.; Lamb, B. J.; Rouillard, J. M.; Kuick, R.; Hanash, S.; Schwartz, D. R.; Fearon, E. R.; Cho, K. R. Amplification and overexpression of the L-MYC proto-oncogene in ovarian carcinomas. Am. J. Pathol., 2003, 162(5), 1603-1610.
17. Zhang, D.; Qi, J.; Liu, R.; Dai, B.; Ma, W.; Zhan, Y.; Zhang, Y. c-Myc plays a key role in TADs-induced apoptosis and cell cycle arrest in human hepatocellular carcinoma cells. Am. J. Cancer Res., 2015, 5(3), 1076-1088.
18. Ramsay, R. G.; Barton, A. L.; Gonda, T. J. Targeting c-Myb expression in human disease. Expert. Opin. Ther. Targets, 2003, 7(2), 235-248.
19. Scotting, P. J.; Walker, D. A.; Perilongo, G. Childhood solid tumours: a developmental disorder. Nat. Rev. Cancer, 2005, 5(6), 481-488
20. Grimmer, M. R.; Weiss, W. A. Childhood tumors of the nervous system as disorders of normal development. Curr. Opin. Pediatr., 2006, 18(6), 634-638.
21. Johnsen, J. I.; Kogner, P.; Albihn, A.; Henriksson, M. A. Embryonal neural tumours and cell death. Apoptosis, 2009, 14(4), 424-438.
22. Momota, H.; Holland, E. C. Mouse models of CNS embryonal tumors. Brain Tumor Pathol., 2009, 26(2), 43-50
23. Eberhart, C. G. Molecular diagnostics in embryonal brain tumors. Brain Pathol., 2011, 21(1), 96-104.
24. Knoepfler, P. S. Myc goes global: new tricks for an old oncogene. Cancer Res., 2007, 67(11), 5061-5063.
25. Hurlin, P. J. N-Myc functions in transcription and development. Birth Defects Res. C. Embryo Today, 2005, 75(4), 340-352.
26. Knoepfler, P. S.; Cheng, P. F.; Eisenman, R. N. N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation. Genes Dev., 2002, 16(20), 2699-2712.
27. Hatton, B. A.; Knoepfler, P. S.; Kenney, A. M.; Rowitch, D. H.; de Alboran, I. M.; Olson, J. M.; Eisenman, R. N. N-myc is an essential downstream effector of Shh signaling during both normal and neoplastic cerebellar growth. Cancer Res., 2006, 66(17), 8655-8661.
28. Swartling, F. J. Myc proteins in brain tumor development and maintenance. Ups J. Med. Sci., 2012, 117(2), 122-131.
29. Pei, Y.; Moore, C. E.; Wang, J.; Tewari, A. K.; Eroshkin, A.; Cho, Y. J.; Witt, H.; Korshunov, A.; Read, T. A.; Sun, J. L.; Schmitt, E. M.; Miller, C. R.; Buckley, A. F.; McLendon, R. E.; Westbrook, T. F.; Northcott, P. A.; Taylor, M. D.; Pfister, S. M.; Febbo, P. G.; Wechsler-Reya, R. J. An animal model of MYCdriven medulloblastoma. Cancer Cell., 2012, 21(2), 155-167
30. Kawauchi, D.; Robinson, G.; Uziel, T.; Gibson, P.; Rehg, J.; Gao, C.; Finkelstein, D.; Qu, C.; Pounds, S.; Ellison, D. W.; Gilbertson, R. J.; Roussel, M. F. A mouse model of the most aggressive subgroup of human medulloblastoma. Cancer Cell., 2012, 21(2), 168-180
31. Kessler, J. D.; Hasegawa, H.; Brun, S. N.; Emmenegger, B. A.; Yang, Z. J.; Dutton, J. W.; Wang, F.; Wechsler-Reya, R. J. N-myc alters the fate of preneoplastic cells in a mouse model of medulloblastoma. Genes Dev., 2009, 23(2), 157-170.
32. Weiss, W. A.; Aldape, K.; Mohapatra, G.; Feuerstein, B. G.; Bishop, J. M. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J., 1997, 16(11), 2985-2995.
33. Kool, M. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One, 2008, 3, e3088
34. Thompson, M. C.; Fuller, C.; Hogg, T. L.; Dalton, J.; Finkelstein, D.; Lau, C. C.; Chintagumpala, M.; Adesina, A.; Ashley, D. M.; Kellie, S. J.; Taylor, M. D.; Curran, T.; Gajjar, A.; Gilbertson, R. J. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J. Clin. Oncol., 2006, 24(12), 1924-1931
35. Northcott, P. A. Medulloblastoma comprises four distinct molecular variants. J. Clin. Oncol., 2011, 29, 1408-1414
36. Remke, M., FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. J. Clin. Oncol., 2011, 29, 3852-3861
37. Taylor, M. D. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol., 2012, 123, 465-472
38. Kool, M. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol., 2012, 123, 473-484.
39. Dang, C. V. MYC on the path to cancer. Cell, 2012, 149(1), 22-35.
40. Gurney, J. G.; Wall, D. A.; Jukich, P. J.; Davis, F. G. The contribution of nonmalignant tumors to CNS tumor incidence rates among children in the United States. Cancer Causes Control, 1999, 10, 102-105.
41. Northcott, P. A. Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. Acta Neuropathol., 2011, 122, 231-240.
42. Packer, R. J.; Hoffman, E. P. Neuro-oncology: understanding the molecular complexity of medulloblastoma. Nat. Rev. Neurol., 2012, 8(10), 539-540.
43. Janz, S. Myc translocations in B cell and plasma cell neoplasms. DNA Repair (Amst), 2006, 5(9-10), 1213-1224.
44. Henderson, B. R.; Fagotto, F. The ins and outs of APC and betacatenin nuclear transport. EMBO Rep., 2002, 3(9), 834-839.
45. Pasqualucci, L.; Neumeister, P.; Goossens, T.; Nanjangud, G.; Chaganti, R. S.; Kuppers, R.; Dalla-Favera, R. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature, 2001, 412(6844), 341-346.
46. Pfister, S. M.; Korshunov, A.; Kool, M.; Hasselblatt, M.; Eberhart, C.; Taylor, M. D. Molecular diagnostics of CNS embryonal tumors. Acta Neuropathol., 2010, 120(5), 553-566.
47. Pfister, S.; Remke, M.; Castoldi, M.; Bai, A. H.; Muckenthaler, M. U.; Kulozik, A.; von Deimling, A.; Pscherer, A.; Lichter, P.; Korshunov, A. Novel genomic amplification targeting the microRNA cluster at 19q13.42 in a pediatric embryonal tumor with abundant neuropil and true rosettes. Acta Neuropathol., 2009, 117(4), 457-464.
48. Takei, H.; Nguyen, Y.; Mehta, V.; Chintagumpala, M.; Dauser, R. C.; Adesina, A. M. Low-level copy gain versus amplification of myc oncogenes in medulloblastoma: utility in predicting prognosis and survival. Laboratory investigation. J. Neurosurg. Pediatr., 2009, 3(1), 61-65.
49. Eberhart, C. G.; Kratz, J.; Wang, Y.; Summers, K.; Stearns, D.; Cohen, K.; Dang, C. V.; Burger, P. C. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J. Neuropathol. Exp. Neurol., 2004, 63(5), 441-449
50. von Hoff, K.; Hartmann, W.; von Bueren, A. O.; Gerber, N. U.; Grotzer, M. A.; Pietsch, T.; Rutkowski, S. Large cell/anaplastic medulloblastoma: outcome according to myc status, histopathological, and clinical risk factors. Pediatr. Blood Cancer, 2010, 54(3), 369-376.
51. Herms, J.; Neidt, I.; Luscher, B.; Sommer, A.; Schurmann, P.; Schroder, T.; Bergmann, M.; Wilken, B.; Probst-Cousin, S.; Hernaiz-Driever, P.; Behnke, J.; Hanefeld, F.; Pietsch, T.; Kretzschmar, H. A. C-myc expression in medulloblastoma and its prognsotic value. Int. J. Cancer, 2000, 89, 395-402.
52. Grotzer, M. A.; Hogarty, M. D.; Janss, A. J.; Liu, X.; Zhao, H.; Eggert, A.; Sutton, L. N.; Rorke, L. B.; Brodeur, G. M.; Phillips, P. C. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin. Cancer Res., 2001, 7(8), 2425-2433.
53. Aldosari, N.; Bigner, S. H.; Burger, P. C.; Becker, L.; Kepner, J. L.; Friedman, H. S.; McLendon, R. E. MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. Arch Pathol Laboratory Med., 2002, 126, 540-545
54. Bayani, J.; Zielenska, M.; Marrano, P.; Kwan Ng, Y.; Taylor, M. D.; Jay, V.; Rutka, J. T.; Squire, J. A. Molecular cytogenetic analysis of medulloblastomas and supratentorial primitive neuroectodermal tumors by using conventional banding, comparative genomic hybridization, and spectral karyotyping. J. Neurosurg., 2000, 93(3), 437-448
55. Eberhart, C. G.; Kratz, J. E.; Schuster, A.; Goldthwaite, P.; Cohen, K. J.; Perlman, E. J.; Burger, P. C. Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/anaplastic medulloblastomas. Brain Pathol., 2002, 12(1), 36-44.
56. Hill, R. M.; Kuijper, S.; Lindsey, J. C.; Petrie, K.; Schwalbe, E. C.; Barker, K.; Boult, J. K.; Williamson, D.; Ahmad, Z.; Hallsworth, A.; Ryan, S. L.; Poon, E.; Robinson, S. P.; Ruddle, R.; Raynaud, F. I.; Howell, L.; Kwok, C.; Joshi, A.; Nicholson, S. L.; Crosier, S.; Ellison, D. W.; Wharton, S. B.; Robson, K.; Michalski, A.; Hargrave, D.; Jacques, T. S.; Pizer, B.; Bailey, S.; Swartling, F. J.; Weiss, W. A.; Chesler, L.; Clifford, S. C. Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease. Cancer Cell, 2015, 27(1), 72-84.
57. Swartling, F. J. Pleiotropic role for MYCN in medulloblastoma. Genes Dev., 2010, 24, 1059-1072.
58. Pfister, S.; Remke, M.; Benner, A.; Mendrzyk, F.; Toedt, G.; Felsberg, J.; Wittmann, A.; Devens, F.; Gerber, N. U.; Joos, S.; Kulozik, A.; Reifenberger, G.; Rutkowski, S.; Wiestler, O. D.; Radlwimmer, B.; Scheurlen, W.; Lichter, P.; Korshunov, A. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J. Clin. Oncol., 2009, 27(10), 1627-1636
59. Pfister, S.; Hartmann, C.; Korshunov, A., Histology and molecular pathology of pediatric brain tumors. J. Child Neurol., 2009, 24(11), 1375-1386.
60. de Haas, T.; Hasselt, N.; Troost, D.; Caron, H.; Popovic, M.; Zadravec-Zaletel, L.; Grajkowska, W.; Perek, M.; Osterheld, M. C.; Ellison, D.; Baas, F.; Versteeg, R.; Kool, M. Molecular risk stratification of medulloblastoma patients based on immunohistochemical analysis of MYC, LDHB, and CCNB1 expression. Clin Cancer Res., 2008, 14(13), 4154-4160.
61. Northcott, P. A. Subgroup-specific structural variation across 1, 000 medulloblastoma genomes. Nature, 2012, 488, 49-56.
62. Roussel, M. F.; Robinson, G. W. Role of MYC in Medulloblastoma. Cold Spring Harb. Perspect. Med., 2013, 3(11)
63. Cho, Y. J. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J. Clin. Oncol., 2011, 29, 1424-1430.
64. Ellison, D. W. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol., 2011, 121, 381-396.
65. Park, A. K.; Lee, S. J.; Phi, J. H.; Wang, K. C.; Kim, D. G.; Cho, B. K.; Haberler, C.; Fattet, S.; Dufour, C.; Puget, S.; Sainte-Rose, C.; Bourdeaut, F.; Grill, J.; Delattre, O.; Kim, S. K.; Park, W. Y. Prognostic classification of pediatric medulloblastoma based on chromosome 17p loss, expression of MYCC and MYCN, and Wnt pathway activation. Neuro. Oncol., 2012, 14(2), 203-214.
66. Jones, D. T.; Jager, N.; Kool, M.; Zichner, T.; Hutter, B.; Sultan, M.; Cho, Y. J.; Pugh, T. J.; Hovestadt, V.; Stutz, A. M.; Rausch, T.; Warnatz, H. J.; Ryzhova, M.; Bender, S.; Sturm, D.; Pleier, S.; Cin, H.; Pfaff, E.; Sieber, L.; Wittmann, A.; Remke, M.; Witt, H.; Hutter, S.; Tzaridis, T.; Weischenfeldt, J.; Raeder, B.; Avci, M.; Amstislavskiy, V.; Zapatka, M.; Weber, U. D.; Wang, Q.; Lasitschka, B.; Bartholomae, C. C.; Schmidt, M.; von Kalle, C.; Ast, V.; Lawerenz, C.; Eils, J.; Kabbe, R.; Benes, V.; van Sluis, P.; Koster, J.; Volckmann, R.; Shih, D.; Betts, M. J.; Russell, R. B.; Coco, S.; Tonini, G. P.; Schuller, U.; Hans, V.; Graf, N.; Kim, Y. J.; Monoranu, C.; Roggendorf, W.; Unterberg, A.; Herold-Mende, C.; Milde, T.; Kulozik, A. E.; von Deimling, A.; Witt, O.; Maass, E.; Rossler, J.; Ebinger, M.; Schuhmann, M. U.; Fruhwald, M. C.; Hasselblatt, M.; Jabado, N.; Rutkowski, S.; von Bueren, A. O.; Williamson, D.; Clifford, S. C.; McCabe, M. G.; Collins, V. P.; Wolf, S.; Wiemann, S.; Lehrach, H.; Brors, B.; Scheurlen, W.; Felsberg, J.; Reifenberger, G.; Northcott, P. A.; Taylor, M. D.; Meyerson, M.; Pomeroy, S. L.; Yaspo, M. L.; Korbel, J. O.; Korshunov, A.; Eils, R.; Pfister, S. M.; Lichter, P. Dissecting the genomic complexity underlying medulloblastoma. Nature, 2012, 488(7409), 100-105
67. Robinson, G.; Parker, M.; Kranenburg, T. A.; Lu, C.; Chen, X.; Ding, L.; Phoenix, T. N.; Hedlund, E.; Wei, L.; Zhu, X.; Chalhoub, N.; Baker, S. J.; Huether, R.; Kriwacki, R.; Curley, N.; Thiruvenkatam, R.; Wang, J.; Wu, G.; Rusch, M.; Hong, X.; Becksfort, J.; Gupta, P.; Ma, J.; Easton, J.; Vadodaria, B.; Onar-Thomas, A.; Lin, T.; Li, S.; Pounds, S.; Paugh, S.; Zhao, D.; Kawauchi, D.; Roussel, M. F.; Finkelstein, D.; Ellison, D. W.; Lau, C. C.; Bouffet, E.; Hassall, T.; Gururangan, S.; Cohn, R.; Fulton, R. S.; Fulton, L. L.; Dooling, D. J.; Ochoa, K.; Gajjar, A.; Mardis, E. R.; Wilson, R. K.; Downing, J. R.; Zhang, J.; Gilbertson, R. J. Novel mutations target distinct subgroups of medulloblastoma. Nature, 2012, 488(7409), 43-48.
68. Northcott, P. A.; Jones, D. T.; Kool, M.; Robinson, G. W.; Gilbertson, R. J.; Cho, Y. J.; Pomeroy, S. L.; Korshunov, A.; Lichter, P.; Taylor, M. D.; Pfister, S. M. Medulloblastomics: the end of the beginning. Nat. Rev. Cancer, 2012, 12(12), 818-834.
69. Parisotto, M.; Metzger, D. Genetically engineered mouse models of prostate cancer. Mol. Oncol., 2013, 7(2), 190-205
70. Stearns, D.; Chaudhry, A.; Abel, T. W.; Burger, P. C.; Dang, C. V.; Eberhart, C. G. c-myc overexpression causes anaplasia in medulloblastoma. Cancer Res., 2006, 66(2), 673-681.
71. Pfister, S. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J. Clin. Oncol., 2009, 27, 1627-1636
72. Northcott, P. A.; Rutka, J. T.; Taylor, M. D. Genomics of medulloblastoma: from Giemsa-banding to next-generation sequencing in 20 years. Neurosurg. Focus., 2010, 28(1), E6
73. Frank, A. J.; Hernan, R.; Hollander, A.; Lindsey, J. C.; Lusher, M. E.; Fuller, C. E.; Clifford, S. C.; Gilbertson, R. J. The TP53-ARF tumor suppressor pathway is frequently disrupted in large/cell anaplastic medulloblastoma. Brain Res. Mol. Brain Res., 2004, 121(1-2), 137-140.
74. Poschl, J.; Stark, S.; Neumann, P.; Grobner, S.; Kawauchi, D.; Jones, D. T.; Northcott, P. A.; Lichter, P.; Pfister, S. M.; Kool, M.; Schuller, U. Genomic and transcriptomic analyses match medulloblastoma mouse models to their human counterparts. Acta Neuropathol., 2014, 128(1), 123-136.
75. Lau, J.; Schmidt, C.; Markant, S. L.; Taylor, M. D.; Wechsler-Reya, R. J.; Weiss, W. A. Matching mice to malignancy: molecular subgroups and models of medulloblastoma. Childs Nerv. Syst., 2012, 28(4), 521-532.
76. Brodeur, G. M. Neuroblastoma: biological insights into a clinical enigma. Nat. Rev. Cancer, 2003, 3(3), 203-16
77. Maris, J. M.; Hogarty, M. D.; Bagatell, R.; Cohn, S. L. Neuroblastoma. Lancet, 2007, 369(9579), 2106-2120
78. Schor, N. F. Neuroblastoma as a neurobiological disease. J. Neurooncol., 1999, 41(2), 159-166
79. Nakagawara, A.; Ohira, M. Comprehensive genomics linking between neural development and cancer: neuroblastoma as a model. Cancer Lett., 2004, 204(2), 213-224.
80. Jiang, M.; Stanke, J.; Lahti, J. M. The connections between neural crest development and neuroblastoma. Curr. Top Dev. Biol., 2011, 94, 77-127.
81. Maris, J. M. The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr. Opin. Pediatr., 2005, 17(1), 7-13.
82. Cohn, S. L.; London, W. B.; Huang, D.; Katzenstein, H. M.; Salwen, H. R.; Reinhart, T.; Madafiglio, J.; Marshall, G. M.; Norris, M. D.; Haber, M. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. J. Clin. Oncol., 2000, 18(21), 3604-3613
83. Wang, L. L.; Teshiba, R.; Ikegaki, N.; Tang, X. X.; Naranjo, A.; London, W. B.; Hogarty, M. D.; Gastier-Foster, J. M.; Look, A. T.; Park, J. R.; Maris, J. M.; Cohn, S. L.; Seeger, R. C.; Asgharzadeh, S.; Shimada, H. Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study. Br. J. Cancer, 2015, 113(1), 57-63
84. Huang, M.; Weiss, W.A. Neuroblastoma and MYCN. Cold Spring Harb. Perspect. Med., 2013, 3(10), a014415.
85. Strieder, V.; Lutz, W. Regulation of N-myc expression in development and disease. Cancer Lett., 2002, 180(2), 107-119.
86. Cui, H.; Li, T.; Ding, H. F. Linking of N-Myc to death receptor machinery in neuroblastoma cells. J. Biol. Chem., 2005, 280(10), 9474-9481
87. Fulda, S.; Lutz, W.; Schwab, M.; Debatin, K. M. MycN sensitizes neuroblastoma cells for drug-induced apoptosis. Oncogene, 1999, 18(7), 1479-1486
88. Lutz, W.; Fulda, S.; Jeremias, I.; Debatin, K. M.; Schwab, M. MycN and IFNgamma cooperate in apoptosis of human neuroblastoma cells. Oncogene, 1998, 17(3), 339-346.
89. Chen, L.; Iraci, N.; Gherardi, S.; Gamble, L. D.; Wood, K. M.; Perini, G.; Lunec, J.; Tweddle, D. A. p53 is a direct transcriptional target of MYCN in neuroblastoma. Cancer Res., 2010, 70(4), 1377-1388.
90. Calin, G. A.; Croce, C. M. Chromosomal rearrangements and microRNAs: a new cancer link with clinical implications. J. Clin. Invest., 2007, 117(8), 2059-2066.
91. Buechner, J.; Einvik, C. N-myc and noncoding RNAs in neuroblastoma. Mol. Cancer Res., 2012, 10(10), 1243-1253.
92. Fontana, L.; Fiori, M. E.; Albini, S.; Cifaldi, L.; Giovinazzi, S.; Forloni, M.; Boldrini, R.; Donfrancesco, A.; Federici, V.; Giacomini, P.; Peschle, C.; Fruci, D. Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS One, 2008, 3(5), e2236
93. Schulte, J. H.; Horn, S.; Otto, T.; Samans, B.; Heukamp, L. C.; Eilers, U. C.; Krause, M.; Astrahantseff, K.; Klein-Hitpass, L.; Buettner, R.; Schramm, A.; Christiansen, H.; Eilers, M.; Eggert, A.; Berwanger, B. MYCN regulates oncogenic MicroRNAs in neuroblastoma. Int. J. Cancer, 2008, 122(3), 699-704
94. Mestdagh, P.; Van Vlierberghe, P.; De Weer, A.; Muth, D.; Westermann, F.; Speleman, F.; Vandesompele, J. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol., 2009, 10(6), R64
95. Loven, J.; Zinin, N.; Wahlstrom, T.; Muller, I.; Brodin, P.; Fredlund, E.; Ribacke, U.; Pivarcsi, A.; Pahlman, S.; Henriksson, M. MYCNregulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma. Proc Natl Acad Sci USA, 2010, 107(4), 1553-1558
96. Bray, I.; Bryan, K.; Prenter, S.; Buckley, P. G.; Foley, N. H.; Murphy, D. M.; Alcock, L.; Mestdagh, P.; Vandesompele, J.; Speleman, F.; London, W. B.; McGrady, P. W.; Higgins, D. G.; O'Meara, A.; O'Sullivan, M.; Stallings, R. L. Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival. PLoS One, 2009, 4(11), e7850
97. Schulte, J. H.; Marschall, T.; Martin, M.; Rosenstiel, P.; Mestdagh, P.; Schlierf, S.; Thor, T.; Vandesompele, J.; Eggert, A.; Schreiber, S.; Rahmann, S.; Schramm, A. Deep sequencing reveals differential expression of microRNAs in favorable versus unfavorable neuroblastoma. Nucleic Acids Res., 2010, 38(17), 5919-5928
98. Shohet, J. M.; Ghosh, R.; Coarfa, C.; Ludwig, A.; Benham, A. L.; Chen, Z.; Patterson, D. M.; Barbieri, E.; Mestdagh, P.; Sikorski, D. N.; Milosavljevic, A.; Kim, E. S.; Gunaratne, P. H. A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma. Cancer Res., 2011, 71(11), 3841-3851
99. Haug, B. H.; Henriksen, J. R.; Buechner, J.; Geerts, D.; Tomte, E.; Kogner, P.; Martinsson, T.; Flaegstad, T.; Sveinbjornsson, B.; Einvik, C. MYCN-regulated miRNA-92 inhibits secretion of the tumor suppressor DICKKOPF-3 (DKK3) in neuroblastoma. Carcinogenesis, 2011, 32(7), 1005-1012
100. De Brouwer, S.; Mestdagh, P.; Lambertz, I.; Pattyn, F.; De Paepe, A.; Westermann, F.; Schroeder, C.; Schulte, J. H.; Schramm, A.; De Preter, K.; Vandesompele, J.; Speleman, F. Dickkopf-3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma. Int. J. Cancer, 2012, 130(11), 2591-2598
101. Shalaby, T.; Fiaschetti, G.; Baumgartner, M.; Grotzer, M. A. Significance and therapeutic value of miRNAs in embryonal neural tumors. Molecules, 2014, 19(5), 5821-5862.
102. Chen, Y.; Stallings, R. L. Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res., 2007, 67(3), 976-983
103. Foley, N. H.; Bray, I. M.; Tivnan, A.; Bryan, K.; Murphy, D. M.; Buckley, P. G.; Ryan, J.; O'Meara, A.; O'Sullivan, M.; Stallings, R. L. MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2. Mol. Cancer, 2010, 9, 83
104. Schulte, J. H.; Schowe, B.; Mestdagh, P.; Kaderali, L.; Kalaghatgi, P.; Schlierf, S.; Vermeulen, J.; Brockmeyer, B.; Pajtler, K.; Thor, T.; de Preter, K.; Speleman, F.; Morik, K.; Eggert, A.; Vandesompele, J.; Schramm, A. Accurate prediction of neuroblastoma outcome based on miRNA expression profiles. Int. J. Cancer, 2010, 127(10), 2374-2385
105. Bray, I.; Tivnan, A.; Bryan, K.; Foley, N. H.; Watters, K. M.; Tracey, L.; Davidoff, A. M.; Stallings, R. L. MicroRNA-542-5p as a novel tumor suppressor in neuroblastoma. Cancer Lett., 2011, 303(1), 56-64.
106. Krutzfeldt, J.; Rajewsky, N.; Braich, R.; Rajeev, K. G.; Tuschl, T.; Manoharan, M.; Stoffel, M. Silencing of microRNAs in vivo with 'antagomirs'. Nature, 2005, 438(7068), 685-689
107. Mendell, J. T. MicroRNAs: critical regulators of development, cellular physiology and malignancy. Cell Cycle, 2005, 4(9), 1179-1184.
108. Hackett, C. S.; Hodgson, J. G.; Law, M. E.; Fridlyand, J.; Osoegawa, K.; de Jong, P. J.; Nowak, N. J.; Pinkel, D.; Albertson, D. G.; Jain, A.; Jenkins, R.; Gray, J. W.; Weiss, W. A. Genomewide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors. Cancer Res., 2003, 63(17), 5266-5273
109. Alam, G.; Cui, H.; Shi, H.; Yang, L.; Ding, J.; Mao, L.; Maltese, W. A.; Ding, H. F. MYCN promotes the expansion of Phox2B-positive neuronal progenitors to drive neuroblastoma development. Am. J. Pathol., 2009, 175(2), 856-66
110. Hansford, L. M.; Thomas, W. D.; Keating, J. M.; Burkhart, C. A.; Peaston, A. E.; Norris, M. D.; Haber, M.; Armati, P. J.; Weiss, W. A.; Marshall, G. M. Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification. Proc. Natl. Acad. Sci. USA, 2004, 101(34), 12664-12669
111. Vandesompele, J.; Speleman, F.; Van Roy, N.; Laureys, G.; Brinskchmidt, C.; Christiansen, H.; Lampert, F.; Lastowska, M.; Bown, N.; Pearson, A.; Nicholson, J. C.; Ross, F.; Combaret, V.; Delattre, O.; Feuerstein, B. G.; Plantaz, D. Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: how many genetic subgroups are there? Med. Pediatr. Oncol., 2001, 36(1), 5-10
112. Iwakura, H.; Ariyasu, H.; Kanamoto, N.; Hosoda, K.; Nakao, K.; Kangawa, K.; Akamizu, T. Establishment of a novel neuroblastoma mouse model. Int. J. Oncol., 2008, 33(6), 1195-1199.
113. Dyer, M. A. Mouse models of childhood cancer of the nervous system. J. Clin. Pathol., 2004, 57(6), 561-576
114. Larson, J. D.; Largaespada, D. A. Review: In vivo models for defining molecular subtypes of the primitive neuroectodermal tumor genome: current challenges and solutions. In Vivo, 2012, 26(4), 487-500.
115. Chen, Z.; Lin, Y.; Barbieri, E.; Burlingame, S.; Hicks, J.; Ludwig, A.; Shohet, J. M. Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo. Neoplasia, 2009, 11(8), 753-762.
116. Burkhart, C. A.; Cheng, A. J.; Madafiglio, J.; Kavallaris, M.; Mili, M.; Marshall, G. M.; Weiss, W. A.; Khachigian, L. M.; Norris, M. D.; Haber, M. Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma. J. Natl. Cancer Inst., 2003, 95(18), 1394-1403.
117. Chesler, L.; Goldenberg, D. D.; Seales, I. T.; Satchi-Fainaro, R.; Grimmer, M.; Collins, R.; Struett, C.; Nguyen, K. N.; Kim, G.; Tihan, T.; Bao, Y.; Brekken, R. A.; Bergers, G.; Folkman, J.; Weiss, W. A. Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma. Cancer Res., 2007, 67(19), 9435-9442.
118. Hogarty, M. D.; Norris, M. D.; Davis, K.; Liu, X.; Evageliou, N. F.; Hayes, C. S.; Pawel, B.; Guo, R.; Zhao, H.; Sekyere, E.; Keating, J.; Thomas, W.; Cheng, N. C.; Murray, J.; Smith, J.; Sutton, R.; Venn, N.; London, W. B.; Buxton, A.; Gilmour, S. K.; Marshall, G. M.; Haber, M. ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. Cancer Res., 2008, 68(23), 9735-9745.
119. Kiyonari, S.; Kadomatsu, K. Neuroblastoma models for insights into tumorigenesis and new therapies. Expert Opin. Drug Discov., 2015, 10(1), 53-62.
120. Swartling, F. J.; Grimmer, M. R.; Hackett, C. S.; Northcott, P. A.; Fan, Q. W.; Goldenberg, D. D.; Lau, J.; Masic, S.; Nguyen, K.; Yakovenko, S.; Zhe, X. N.; Gilmer, H. C.; Collins, R.; Nagaoka, M.; Phillips, J. J.; Jenkins, R. B.; Tihan, T.; Vandenberg, S. R.; James, C. D.; Tanaka, K.; Taylor, M. D.; Weiss, W. A.; Chesler, L. Pleiotropic role for MYCN in medulloblastoma. Genes Dev., 2010, 24(10), 1059-1072.
121. Teitz, T.; Inoue, M.; Valentine, M. B.; Zhu, K.; Rehg, J. E.; Zhao, W.; Finkelstein, D.; Wang, Y. D.; Johnson, M. D.; Calabrese, C.; Rubinstein, M.; Hakem, R.; Weiss, W. A.; Lahti, J. M. Th-MYCN mice with caspase-8 deficiency develop advanced neuroblastoma with bone marrow metastasis. Cancer Res., 2013, 73(13), 4086-4097.
122. Althoff, K.; Beckers, A.; Bell, E.; Nortmeyer, M.; Thor, T.; Sprussel, A.; Lindner, S.; De Preter, K.; Florin, A.; Heukamp, L. C.; Klein-Hitpass, L.; Astrahantseff, K.; Kumps, C.; Speleman, F.; Eggert, A.; Westermann, F.; Schramm, A.; Schulte, J. H. A Creconditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies. Oncogene, 2015, 34(26), 3357-3368.
123. Berry, T.; Luther, W.; Bhatnagar, N.; Jamin, Y.; Poon, E.; Sanda, T.; Pei, D.; Sharma, B.; Vetharoy, W. R.; Hallsworth, A.; Ahmad, Z.; Barker, K.; Moreau, L.; Webber, H.; Wang, W.; Liu, Q.; Perez-Atayde, A.; Rodig, S.; Cheung, N. K.; Raynaud, F.; Hallberg, B.; Robinson, S. P.; Gray, N. S.; Pearson, A. D.; Eccles, S. A.; Chesler, L.; George, R. E. The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell, 2012, 22(1), 117-130.
124. Gurel, B.; Iwata, T.; Koh, C. M.; Jenkins, R. B.; Lan, F.; Van Dang, C.; Hicks, J. L.; Morgan, J.; Cornish, T. C.; Sutcliffe, S.; Isaacs, W. B.; Luo, J.; De Marzo, A. M. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol., 2008, 21(9), 1156-1167
125. Palaskas, N.; Larson, S. M.; Schultz, N.; Komisopoulou, E.; Wong, J.; Rohle, D.; Campos, C.; Yannuzzi, N.; Osborne, J. R.; Linkov, I.; Kastenhuber, E. R.; Taschereau, R.; Plaisier, S. B.; Tran, C.; Heguy, A.; Wu, H.; Sander, C.; Phelps, M. E.; Brennan, C.; Port, E.; Huse, J. T.; Graeber, T. G.; Mellinghoff, I. K. 18F-fluorodeoxyglucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers. Cancer Res., 2011, 71(15), 5164-5174.
126. Morton, J. P.; Sansom, O. J. MYC-y mice: from tumour initiation to therapeutic targeting of endogenous MYC. Mol. Oncol., 2013, 7(2), 248-258
127. Brondfield, S.; Umesh, S.; Corella, A.; Zuber, J.; Rappaport, A. R.; Gaillard, C.; Lowe, S. W.; Goga, A.; Kogan, S. C. Direct and indirect targeting of MYC to treat acute myeloid leukemia. Cancer Chemother. Pharmacol., 2015, 76(1), 35-46.
128. Fukazawa, T.; Maeda, Y.; Matsuoka, J.; Yamatsuji, T.; Shigemitsu, K.; Morita, I.; Faiola, F.; Durbin, M. L.; Soucek, L.; Naomoto, Y. Inhibition of Myc effectively targets KRAS mutation-positive lung cancer expressing high levels of Myc. Anticancer Res., 2010, 30(10), 4193-4200.
129. Felsher, D. W.; Bishop, J. M., Reversible tumorigenesis by MYC in hematopoietic lineages. Mol. Cell, 1999, 4(2), 199-207.
130. D'Cruz, C. M.; Gunther, E. J.; Boxer, R. B.; Hartman, J. L.; Sintasath, L.; Moody, S. E.; Cox, J. D.; Ha, S. I.; Belka, G. K.; Golant, A.; Cardiff, R. D.; Chodosh, L. A. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat. Med., 2001, 7(2), 235-239.
131. Pelengaris, S.; Khan, M.; Evan, G. I. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell, 2002, 109(3), 321-334.
132. Shachaf, C. M.; Kopelman, A. M.; Arvanitis, C.; Karlsson, A.; Beer, S.; Mandl, S.; Bachmann, M. H.; Borowsky, A. D.; Ruebner, B.; Cardiff, R. D.; Yang, Q.; Bishop, J. M.; Contag, C. H.; Felsher, D. W. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature, 2004, 431(7012), 1112-1117.
133. Arnold, I.; Watt, F. M. c-Myc activation in transgenic mouse epidermis results in mobilization of stem cells and differentiation of their progeny. Curr. Biol., 2001, 11(8), 558-568.
134. Yu, D.; Dews, M.; Park, A.; Tobias, J. W.; Thomas-Tikhonenko, A. Inactivation of Myc in murine two-hit B lymphomas causes dormancy with elevated levels of interleukin 10 receptor and CD20: implications for adjuvant therapies. Cancer Res., 2005, 65(12), 5454-5461.
135. Vita, M.; Henriksson, M. The Myc oncoprotein as a therapeutic target for human cancer. Semin. Cancer Biol., 2006, 16(4), 318-330.
136. Yang, D.; Hurley, L. H. Structure of the biologically relevant Gquadruplex in the c-MYC promoter. Nucleosides Nucleotides Nucleic Acids, 2006, 25(8), 951-968.
137. Shalaby, T.; Fiaschetti, G.; Nagasawa, K.; Shin-Ya, K.; Baumgartner, M.; Grotzer, M. G-quadruplexes as potential therapeutic targets for embryonal tumors. Molecules, 2013, 18(10), 12500-12537.
138. Nasiri, H. R.; Bell, N. M.; McLuckie, K. I.; Husby, J.; Abell, C.; Neidle, S.; Balasubramanian, S. Targeting a c-MYC G-quadruplex DNA with a fragment library. Chem. Commun. (Camb), 2014, 50(14), 1704-1707
139. Seenisamy, J.; Bashyam, S.; Gokhale, V.; Vankayalapati, H.; Sun, D.; Siddiqui-Jain, A.; Streiner, N.; Shin-Ya, K.; White, E.; Wilson, W. D.; Hurley, L. H. Design and synthesis of an expanded porphyrin that has selectivity for the c Current Cancer Drug Targets, 2016, Vol. 16, No. 1 Shalaby and Grotzer MYC G-quadruplex structure. J. Am. Chem. Soc., 2005, 127(9), 2944-2959.
140. Ou, T. M.; Lu, Y. J.; Tan, J. H.; Huang, Z. S.; Wong, K. Y. and Gu, L. Q. G-quadruplexes: targets in anticancer drug design. Chem.Med.Chem., 2008, 3(5), 690-713
141. Ou, T. M.; Lin, J.; Lu, Y. J.; Hou, J. Q.; Tan, J. H.; Chen, S. H.; Li, Z.; Li, Y. P.; Li, D.; Gu, L. Q.; Huang, Z. S. Inhibition of cell proliferation by quindoline derivative (SYUIQ-05) through its preferential interaction with c-myc promoter G-quadruplex. J. Med. Chem., 2011, 54(16), 5671-5679
142. Ou, T. M.; Lu, Y. J.; Zhang, C.; Huang, Z. S.; Wang, X. D.; Tan, J. H.; Chen, Y.; Ma, D. L.; Wong, K. Y.; Tang, J. C.; Chan, A. S.; Gu, L. Q. Stabilization of Gquadruplex DNA and down-regulation of oncogene c-myc by quindoline derivatives. J. Med. Chem., 2007, 50(7), 1465-1474.
143. Kerwin, S. M.; Chen, G.; Kern, J. T.; Thomas, P. W. Perylene diimide G-quadruplex DNA binding selectivity is mediated by ligand aggregation. Bioorg. Med. Chem. Lett., 2002, 12(3), 447-450.
144. Shalaby, T.; Hiyama, E.; Grotzer, M. A. Telomere maintenance as therapeutic target in embryonal tumours. Anticancer Agents Med. Chem., 2010, 10(3), 196-212
145. Shalaby, T.; von Bueren, A. O.; Hurlimann, M. L.; Fiaschetti, G.; Castelletti, D.; Masayuki, T.; Nagasawa, K.; Arcaro, A.; Jelesarov, I.; Shin-Ya, K.; Grotzer, M. Disabling c-Myc in childhood medulloblastoma and atypical teratoid/rhabdoid tumor cells by the potent G-quadruplex interactive agent S2T1-6OTD. Mol. Cancer Ther., 2010, 9(1), 167-179.
146. Ji, X.; Sun, H.; Zhou, H.; Xiang, J.; Tang, Y.; Zhao, C., The interaction of telomeric DNA and C-myc22 G-quadruplex with 11 natural alkaloids. Nucleic Acid Ther., 2012, 22(2), 127-136
147. Zhang, W. J.; Ou, T. M.; Lu, Y. J.; Huang, Y. Y.; Wu, W. B.; Huang, Z. S.; Zhou, J. L.; Wong, K. Y.; Gu, L. Q. 9-Substituted berberine derivatives as G-quadruplex stabilizing ligands in telomeric DNA. Bioorg. Med. Chem., 2007, 15(16), 5493-5501.
148. Monchaud, D.; Teulade-Fichou, M. P. A hitchhiker's guide to G-quadruplex ligands. Org. Biomol. Chem., 2008, 6(4), 627-636
149. Wang, J.; Lu, K.; Xuan, S.; Toh, Z.; Zhang, D.; Shao, F. A Pt(II)-Dip complex stabilizes parallel c-myc G-quadruplex. Chem. Commun. (Camb), 2013, 49(42), 4758-4760
150. Zhang, J.; Zhang, F.; Li, H.; Liu, C.; Xia, J.; Ma, L.; Chu, W.; Zhang, Z.; Chen, C.; Li, S.; Wang, S. Recent progress and future potential for metal complexes as anticancer drugs targeting G-quadruplex DNA. Curr. Med. Chem., 2012, 19(18), 2957-2975.
151. Brooks, T. A.; Hurley, L. H. Targeting MYC Expression through G-Quadruplexes. Genes Cancer, 2010, 1(6), 641-649
152. Brooks, T. A.; Hurley, L. H. The role of supercoiling in transcriptional control of MYC and its importance in molecular therapeutics. Nat. Rev. Cancer, 2009, 9(12), 849-861
153. Steele, N. L.; Plumb, J. A.; Vidal, L.; Tjornelund, J.; Knoblauch, P.; Rasmussen, A.; Ooi, C. E.; Buhl-Jensen, P.; Brown, R.; Evans, T. R.; DeBono, J. S. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin. Cancer Res., 2008, 14(3), 804-810.
154. Chen, B. J.; Wu, Y. L.; Tanaka, Y.; Zhang, W. Small molecules targeting c-Myc oncogene: promising anti-cancer therapeutics. Int. J. Biol. Sci., 2014, 10(10), 1084-1096.
155. Pooga, M.; Kut, C.; Kihlmark, M.; Hallbrink, M.; Fernaeus, S.; Raid, R.; Land, T.; Hallberg, E.; Bartfai, T.; Langel, U. Cellular translocation of proteins by transportan. Faseb J., 2001, 15(8), 1451-3
156. Grotzer, M. A.; Castelletti, D.; Fiaschetti, G.; Shalaby, T.; Arcaro, A. Targeting Myc in pediatric malignancies of the central and peripheral nervous system. Curr. Cancer Drug Targets, 2009, 9(2), 176-188.
157. Wang, Y. H.; Liu, S.; Zhang, G.; Zhou, C. Q.; Zhu, H. X.; Zhou, X. B.; Quan, L. P.; Bai, J. F.; Xu, N. Z. Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo. Breast Cancer Res., 2005, 7(2), R220-R228
158. Li, C. M.; Margolin, A. A.; Salas, M.; Memeo, L.; Mansukhani, M.; Hibshoosh, H.; Szabolcs, M.; Klinakis, A.; Tycko, B. PEG10 is a c-MYC target gene in cancer cells. Cancer Res., 2006, 66(2), 665-672.
159. Delmore, J. E.; Issa, G. C.; Lemieux, M. E.; Rahl, P. B.; Shi, J.; Jacobs, H. M.; Kastritis, E.; Gilpatrick, T.; Paranal, R. M.; Qi, J.; Chesi, M.; Schinzel, A. C.; McKeown, M. R.; Heffernan, T. P.; Vakoc, C. R.; Bergsagel, P. L.; Ghobrial, I. M.; Richardson, P. G.; Young, R. A.; Hahn, W. C.; Anderson, K. C.; Kung, A. L.; Bradner, J. E.; Mitsiades, C. S. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell, 2011, 146(6), 904-917
160. Filippakopoulos, P.; Knapp, S. The bromodomain interaction module. FEBS Lett., 2012, 586(17), 2692-2704.
161. Wang, H.; Sharma, L.; Lu, J.; Finch, P.; Fletcher, S.; Prochownik, E. V. Structurally diverse c-Myc inhibitors share a common mechanism of action involving ATP depletion. Oncotarget, 2015, 6(18), 15857-15870.
162. Mertz, J. A.; Conery, A. R.; Bryant, B. M.; Sandy, P.; Balasubramanian, S.; Mele, D. A.; Bergeron, L.; Sims, R. J., 3rd, Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl. Acad. Sci. USA, 2011, 108(40), 16669-16674.
163. Herrmann, H.; Blatt, K.; Shi, J.; Gleixner, K. V.; Cerny-Reiterer, S.; Mullauer, L.; Vakoc, C. R.; Sperr, W. R.; Horny, H. P.; Bradner, J. E.; Zuber, J.; Valent, P. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem-and progenitor cells in acute myeloid leukemia AML. Oncotarget, 2012, 3(12), 1588-1599.
164. Puissant, A.; Frumm, S. M.; Alexe, G.; Bassil, C. F.; Qi, J.; Chanthery, Y. H.; Nekritz, E. A.; Zeid, R.; Gustafson, W. C.; Greninger, P.; Garnett, M. J.; McDermott, U.; Benes, C. H.; Kung, A. L.; Weiss, W. A.; Bradner, J. E.; Stegmaier, K. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov., 2013, 3(3), 308-323.
165. Bandopadhayay, P.; Bergthold, G.; Nguyen, B.; Schubert, S.; Gholamin, S.; Tang, Y.; Bolin, S.; Schumacher, S. E.; Zeid, R.; Masoud, S.; Yu, F.; Vue, N.; Gibson, W. J.; Paolella, B. R.; Mitra, S. S.; Cheshier, S. H.; Qi, J.; Liu, K. W.; Wechsler-Reya, R.; Weiss, W. A.; Swartling, F. J.; Kieran, M. W.; Bradner, J. E.; Beroukhim, R.; Cho, Y. J. BET Bromodomain Inhibition of MYCAmplified Medulloblastoma. Clin. Cancer Res., 2014, 20(4), 912-925.
166. Zuber, J.; Shi, J.; Wang, E.; Rappaport, A. R.; Herrmann, H.; Sison, E. A.; Magoon, D.; Qi, J.; Blatt, K.; Wunderlich, M.; Taylor, M. J.; Johns, C.; Chicas, A.; Mulloy, J. C.; Kogan, S. C.; Brown, P.; Valent, P.; Bradner, J. E.; Lowe, S. W.; Vakoc, C. R. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature, 2011, 478(7370), 524-528.
167. Chio, II; Yordanov, G.; Tuveson, D., MAX-ing out MYC: a novel small molecule inhibitor against MYC-dependent tumors. J. Natl. Cancer Inst., 2014, 106(12)
168. Lockwood, W. W.; Zejnullahu, K.; Bradner, J. E.; Varmus, H., Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc Natl Acad Sci U S A 2012, 109 (47), 19408-19413
169. Fowler, T.; Ghatak, P.; Price, D. H.; Conaway, R.; Conaway, J.; Chiang, C. M.; Bradner, J. E.; Shilatifard, A.; Roy, A. L. Regulation of MYC expression and differential JQ1 sensitivity in cancer cells. PLoS One, 2014, 9(1), e87003.
170. El-Andaloussi, S.; Johansson, H.; Magnusdottir, A.; Jarver, P.; Lundberg, P.; Langel, U. TP10, a delivery vector for decoy oligonucleotides targeting the Myc protein. J. Control Release, 2005, 110(1), 189-201.
171. Seki, Y.; Yamamoto, H.; Ngan, C. Y.; Yasui, M.; Tomita, N.; Kitani, K.; Takemasa, I.; Ikeda, M.; Sekimoto, M.; Matsuura, N.; Albanese, C.; Kaneda, Y.; Pestell, R. G.; Monden, M. Construction of a novel DNA decoy that inhibits the oncogenic beta-catenin/Tcell factor pathway. Mol Cancer Ther 2006, 5 (4), 985-994.
172. Popov, N.; Wanzel, M.; Madiredjo, M.; Zhang, D.; Beijersbergen, R.; Bernards, R.; Moll, R.; Elledge, S. J.; Eilers, M. The ubiquitinspecific protease USP28 is required for MYC stability. Nat. Cell Biol., 2007, 9(7), 765-774.
173. Berg, T.; Cohen, S. B.; Desharnais, J.; Sonderegger, C.; Maslyar, D. J.; Goldberg, J.; Boger, D. L.; Vogt, P. K. Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. Proc. Natl. Acad. Sci. USA, 2002, 99(6), 3830-3835.
174. Yin, X.; Giap, C.; Lazo, J. S.; Prochownik, E. V. Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene, 2003, 22(40), 6151-6159
175. Xu, Y.; Shi, J.; Yamamoto, N.; Moss, J. A.; Vogt, P. K.; Janda, K. D. A credit-card library approach for disrupting protein-protein interactions. Bioorg. Med. Chem., 2006, 14(8), 2660-2673
176. Clausen, D. M.; Guo, J.; Parise, R. A.; Beumer, J. H.; Egorin, M. J.; Lazo, J. S.; Prochownik, E. V.; Eiseman, J. L. In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization. J. Pharmacol. Exp. Ther., 2010, 335(3), 715-727
177. Follis, A. V.; Hammoudeh, D. I.; Daab, A. T.; Metallo, S. J. Small-molecule perturbation of competing interactions between c-Myc and Max. Bioorg. Med. Chem. Lett., 2009, 19(3), 807-810
178. Hammoudeh, D. I.; Follis, A. V.; Prochownik, E. V.; Metallo, S. J. Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc. J. Am. Chem. Soc., 2009, 131(21), 7390-7401
179. Prochownik, E. V.; Vogt, P. K. Therapeutic Targeting of Myc. Genes Cancer, 2010, 1(6), 650-659
180. Wang, H.; Hammoudeh, D. I.; Follis, A. V.; Reese, B. E.; Lazo, J. S.; Metallo, S. J.; Prochownik, E. V. Improved low molecular weight Myc-Max inhibitors. Mol. Cancer Ther., 2007, 6(9), 2399-2408.
181. Mo, H.; Henriksson, M. Identification of small molecules that induce apoptosis in a Myc-dependent manner and inhibit Myc-driven transformation. Proc. Natl. Acad. Sci. USA, 2006, 103(16), 6344-6349.
182. Kiessling, A.; Sperl, B.; Hollis, A.; Eick, D.; Berg, T. Selective inhibition of c-Myc/Max dimerization and DNA binding by small molecules. Chem. Biol., 2006, 13 (7), 745-751
183. Mo, H.; Vita, M.; Crespin, M.; Henriksson, M. Myc overexpression enhances apoptosis induced by small molecules. Cell Cycle, 2006, 5(19), 2191-2194.
184. Conacci-Sorrell, M.; McFerrin, L.; Eisenman, R. N. An overview of MYC and its interactome. Cold Spring Harb. Perspect. Med., 2014, 4(1), a014357.
185. Kota, J.; Chivukula, R. R.; O'Donnell, K. A.; Wentzel, E. A.; Montgomery, C. L.; Hwang, H. W.; Chang, T. C.; Vivekanandan, P.; Torbenson, M.; Clark, K. R.; Mendell, J. R.; Mendell, J. T. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell, 2009, 137(6), 1005-1017.
186. Frenzel, A.; Loven, J.; Henriksson, M. A. Targeting MYC-Regulated miRNAs to Combat Cancer. Genes Cancer, 2010, 1(6), 660-667.
187. Ma, L.; Young, J.; Prabhala, H.; Pan, E.; Mestdagh, P.; Muth, D.; Teruya-Feldstein, J.; Reinhardt, F.; Onder, T. T.; Valastyan, S.; Westermann, F.; Speleman, F.; Vandesompele, J.; Weinberg, R. A. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat. Cell Biol., 2010, 12(3), 247-256.
188. Le, A.; Cooper, C. R.; Gouw, A. M.; Dinavahi, R.; Maitra, A.; Deck, L. M.; Royer, R. E.; Vander Jagt, D. L.; Semenza, G. L.; Dang, C. V. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc. Natl. Acad. Sci. USA, 2010, 107(5), 2037-2042
189. Seltzer, M. J.; Bennett, B. D.; Joshi, A. D.; Gao, P.; Thomas, A. G.; Ferraris, D. V.; Tsukamoto, T.; Rojas, C. J.; Slusher, B. S.; Rabinowitz, J. D.; Dang, C. V.; Riggins, G. J. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res., 2010, 70(22), 8981-8987
190. Seth, P.; Grant, A.; Tang, J.; Vinogradov, E.; Wang, X.; Lenkinski, R.; Sukhatme, V. P. Ontarget inhibition of tumor fermentative glycolysis as visualized by hyperpolarized pyruvate. Neoplasia, 2011, 13(1), 60-71.
191. den Hollander, J.; Rimpi, S.; Doherty, J. R.; Rudelius, M.; Buck, A.; Hoellein, A.; Kremer, M.; Graf, N.; Scheerer, M.; Hall, M. A.; Goga, A.; von Bubnoff, N.; Duyster, J.; Peschel, C.; Cleveland, J. L.; Nilsson, J. A.; Keller, U. Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood, 2010, 116(9), 1498-1505
192. Yang, D.; Liu, H.; Goga, A.; Kim, S.; Yuneva, M.; Bishop, J. M. Therapeutic potential of a synthetic lethal interaction between the MYC protooncogene and inhibition of aurora-B kinase. Proc. Natl. Acad. Sci. USA, 2010, 107(31), 13836-13841.
193. Kessler, J. D.; Kahle, K. T.; Sun, T.; Meerbrey, K. L.; Schlabach, M. R.; Schmitt, E. M.; Skinner, S. O.; Xu, Q.; Li, M. Z.; Hartman, Z. C.; Rao, M.; Yu, P.; Dominguez-Vidana, R.; Liang, A. C.; Solimini, N. L.; Bernardi, R. J.; Yu, B.; Hsu, T.; Golding, I.; Luo, J.; Osborne, C. K.; Creighton, C. J.; Hilsenbeck, S. G.; Schiff, R.; Shaw, C. A.; Elledge, S. J.; Westbrook, T. F. A SUMOylationdependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science, 2012, 335(6066), 348-353.
194. McKeown, M. R.; Bradner, J. E. Therapeutic strategies to inhibit MYC. Cold Spring Harb. Perspect. Med., 4 (10)
195. Sewastianik, T.; Prochorec-Sobieszek, M.; Chapuy, B.; Juszczynski, P. MYC deregulation in lymphoid tumors: molecular mechanisms, clinical consequences and therapeutic implications. Biochim. Biophys. Acta, 1846 (2), 457-467.
196. Ma, Y.; Ou, T. M.; Hou, J. Q.; Lu, Y. J.; Tan, J. H.; Gu, L. Q.; Huang, Z. S. 9-N-Substituted berberine derivatives: stabilization of G-quadruplex DNA and down-regulation of oncogene c-myc. Bioorg. Med. Chem., 2008, 16(16), 7582-7591.
197. Soucek, L.; Whitfield, J. R.; Sodir, N. M.; Masso-Valles, D.; Serrano, E.; Karnezis, A. N.; Swigart, L. B.; Evan, G. I. Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev., 2013, 27(5), 504-513.
198. Stellas, D.; Szabolcs, M.; Koul, S.; Li, Z.; Polyzos, A.; Anagnostopoulos, C.; Cournia, Z.; Tamvakopoulos, C.; Klinakis, A.; Efstratiadis, A. Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer. J. Natl. Cancer Inst., 2014, 106(12), pii: dju320. doi: 10.1093/jnci/dju320.
199. Ikezoe, T.; Nishioka, C.; Bandobashi, K.; Yang, Y.; Kuwayama, Y.; Adachi, Y.; Takeuchi, T.; Koeffler, H. P.; Taguchi, H. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells. Leuk. Res., 2007, 31(5), 673-682.
200. Rahl, P. B.; Lin, C. Y.; Seila, A. C.; Flynn, R. A.; McCuine, S.; Burge, C. B.; Sharp, P. A.; Young, R. A. c-Myc regulates transcriptional pause release. Cell, 141 (3), 432-445.
201. Felsher, D. W.; Zetterberg, A.; Zhu, J.; Tlsty, T.; Bishop, J. M. Overexpression of MYC causes p53-dependent G2 arrest of normal fibroblasts. Proc. Natl. Acad. Sci. USA, 2000, 97(19), 10544-10548.
202. Tian, X. H.; Hou, W. J.; Fang, Y.; Fan, J.; Tong, H.; Bai, S. L.; Chen, Q.; Xu, H.; Li, Y. XAV939, a tankyrase 1 inhibitior, promotes cell apoptosis in neuroblastoma cell lines by inhibiting Wnt/beta-catenin signaling pathway. J. Exp. Clin. Cancer Res., 2013, 32, 100.
203. Moellering, R. E.; Cornejo, M.; Davis, T. N.; Del Bianco, C.; Aster, J. C.; Blacklow, S. C.; Kung, A. L.; Gilliland, D. G.; Verdine, G. L.; Bradner, J. E. Direct inhibition of the NOTCH transcription factor complex. Nature, 2009, 462(7270), 182-188.
204. Cerutti, J.; Trapasso, F.; Battaglia, C.; Zhang, L.; Martelli, M. L.; Visconti, R.; Berlingieri, M. T.; Fagin, J. A.; Santoro, M.; Fusco, A. Block of c-myc expression by antisense oligonucleotides inhibits proliferation of human thyroid carcinoma cell lines. Clin. Cancer Res., 1996, 2(1), 119-126
205. von Bueren, A. O.; Shalaby, T.; Oehler-Janne, C.; Arnold, L.; Stearns, D.; Eberhart, C. G.; Arcaro, A.; Pruschy, M.; Grotzer, M. A. RNA interference-mediated c-MYC inhibition prevents cell growth and decreases sensitivity to radio-and chemotherapy in childhood medulloblastoma cells. BMC Cancer, 2009, 9(1), 10.
206. von Bueren, A. O.; Shalaby, T.; Rajtarova, J.; Stearns, D.; Eberhart, C. G.; Helson, L.; Arcaro, A.; Grotzer, M. A. Anti-proliferative activity of the quassinoid NBT-272 in childhood medulloblastoma cells. BMC Cancer, 2007, 7(1), 19.
207. Morfouace, M.; Shelat, A.; Jacus, M.; Freeman, B. B., 3rd; Turner, D.; Robinson, S.; Zindy, F.; Wang, Y. D.; Finkelstein, D.; Ayrault, O.; Bihannic, L.; Puget, S.; Li, X. N.; Olson, J. M.; Robinson, G. W.; Guy, R. K.; Stewart, C. F.; Gajjar, A.; Roussel, M. F. Pemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma. Cancer Cell, 25 (4), 516-529.
208. Henssen, A.; Thor, T.; Odersky, A.; Heukamp, L.; El-Hindy, N.; Beckers, A.; Speleman, F.; Althoff, K.; Schafers, S.; Schramm, A.; Sure, U.; Fleischhack, G.; Eggert, A.; Schulte, J. H. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma. Oncotarget, 2013, 4(11), 2080-2095.
209. Sengupta, S.; Weeraratne, S. D.; Sun, H.; Phallen, J.; Rallapalli, S. K.; Teider, N.; Kosaras, B.; Amani, V.; Pierre-Francois, J.; Tang, Y.; Nguyen, B.; Yu, F.; Schubert, S.; Balansay, B.; Mathios, D.; Lechpammer, M.; Archer, T. C.; Tran, P.; Reimer, R. J.; Cook, J. M.; Lim, M.; Jensen, F. E.; Pomeroy, S. L.; Cho, Y. J. alpha5-GABAA receptors negatively regulate MYC-amplified medulloblastoma growth. Acta Neuropathol., 2014, 127(4), 593-603
210. Kang, J. H.; Rychahou, P. G.; Ishola, T. A.; Qiao, J.; Evers, B. M.; Chung, D. H. MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells. Biochem. Biophys. Res. Commun., 2006, 351(1), 192-197.
211. Ponthan, F.; Lindskog, M.; Karnehed, N.; Castro, J.; Kogner, P. Evaluation of anti-tumour effects of oral fenretinide (4-HPR) in rats with human neuroblastoma xenografts. Oncol. Rep., 2003, 10(5), 1587-1592.
212. Pession, A.; Tonelli, R.; Fronza, R.; Sciamanna, E.; Corradini, R.; Sforza, S.; Tedeschi, T.; Marchelli, R.; Montanaro, L.; Camerin, C.; Franzoni, M.; Paolucci, G. Targeted inhibition of NMYC by peptide nucleic acid in N-myc amplified human neuroblastoma cells: cell-cycle inhibition with induction of neuronal cell differentiation and apoptosis. Int. J. Oncol., 2004, 24(2), 265-272.
213. Sun, L.; Fuselier, J. A.; Murphy, W. A.; Coy, D. H. Antisense peptide nucleic acids conjugated to somatostatin analogs and targeted at the n-myc oncogene display enhanced cytotoxity to human neuroblastoma IMR32 cells expressing somatostatin receptors. Peptides, 2002, 23(9), 1557-1565.
214. Sarkar, C.; Deb, P.; Sharma, M. C. Recent advances in embryonal tumours of the central nervous system. Childs Nerv. Syst., 2005, 21(4), 272-293.
215. Radhakrishnan, S. K.; Halasi, M.; Bhat, U. G.; Kurmasheva, R. T.; Houghton, P. J.; Gartel, A. L. Proapoptotic compound ARC targets Akt and N-myc in neuroblastoma cells. Oncogene, 2008, 27(5), 694-699.
216. Liu, J.; Guo, L.; Yin, F.; Zheng, X.; Chen, G.; Wang, Y. Characterization and antitumor activity of triethylene tetramine, a novel telomerase inhibitor. Biomed. Pharmacother., 2008, 62(7), 480-485.
217. Gamble, L. D.; Kees, U. R.; Tweddle, D. A.; Lunec, J. MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63. Oncogene, 2012, 31(6), 752-763.
218. Carr-Wilkinson, J.; O'Toole, K.; Wood, K. M.; Challen, C. C.; Baker, A. G.; Board, J. R.; Evans, L.; Cole, M.; Cheung, N. K.; Boos, J.; Kohler, G.; Leuschner, I.; Pearson, A. D.; Lunec, J.; Tweddle, D. A. High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma. Clin. Cancer Res., 2010, 16(4), 1108-1118.
219. Chesler, L.; Schlieve, C.; Goldenberg, D. D.; Kenney, A.; Kim, G.; McMillan, A.; Matthay, K. K.; Rowitch, D.; Weiss, W. A. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res., 2006, 66(16), 8139-8146.
220. Chanthery, Y. H.; Gustafson, W. C.; Itsara, M.; Persson, A.; Hackett, C. S.; Grimmer, M.; Charron, E.; Yakovenko, S.; Kim, G.; Matthay, K. K.; Weiss, W. A. Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma. Sci. Transl. Med., 2012, 4(115), 115ra3.
221. Hogarty, M. D.; Maris, J. M. PI3King on MYCN to improve neuroblastoma therapeutics. Cancer Cell, 2012, 21(2), 145-147.
222. Rounbehler, R. J.; Li, W.; Hall, M. A.; Yang, C.; Fallahi, M.; Cleveland, J. L. Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma. Cancer Res., 2009, 69(2), 547-53.
223. Carol, H.; Boehm, I.; Reynolds, C. P.; Kang, M. H.; Maris, J. M.; Morton, C. L.; Gorlick, R.; Kolb, E. A.; Keir, S. T.; Wu, J.; Wozniak, A. E.; Yang, Y.; Manfredi, M.; Ecsedy, J.; Wang, J.; Neale, G.; Houghton, P. J.; Smith, M. A.; Lock, R. B. Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemother. Pharmacol., 2011, 68(5), 1291-1304.
224. Maris, J. M.; Morton, C. L.; Gorlick, R.; Kolb, E. A.; Lock, R.; Carol, H.; Keir, S. T.; Reynolds, C. P.; Kang, M. H.; Wu, J.; Smith, M. A.; Houghton, P. J. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr. Blood Cancer, 2010, 55(1), 26-34.
225. Faisal, A.; Vaughan, L.; Bavetsias, V.; Sun, C.; Atrash, B.; Avery, S.; Jamin, Y.; Robinson, S. P.; Workman, P.; Blagg, J.; Raynaud, F. I.; Eccles, S. A.; Chesler, L.; Linardopoulos, S. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo. Mol. Cancer Ther., 2011, 10(11), 2115-2123.
226. Schramm, A.; Koster, J.; Marschall, T.; Martin, M.; Schwermer, M.; Fielitz, K.; Buchel, G.; Barann, M.; Esser, D.; Rosenstiel, P.; Rahmann, S.; Eggert, A.; Schulte, J. H. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma. Int. J. Cancer, 2013, 132(3), E106-E115.
227. Creevey, L.; Ryan, J.; Harvey, H.; Bray, I. M.; Meehan, M.; Khan, A. R.; Stallings, R. L. MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1. Mol. Cancer, 2013, 12, 23.
228. Glade Bender, J. L.; Adamson, P. C.; Reid, J. M.; Xu, L.; Baruchel, S.; Shaked, Y.; Kerbel, R. S.; Cooney-Qualter, E. M.; Stempak, D.; Chen, H. X.; Nelson, M. D.; Krailo, M. D.; Ingle, A. M.; Blaney, S. M.; Kandel, J. J.; Yamashiro, D. J. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J. Clin. Oncol., 2008, 26(3), 399-405
229. Navid, F.; Baker, S. D.; McCarville, M. B.; Stewart, C. F.; Billups, C. A.; Wu, J.; Davidoff, A. M.; Spunt, S. L.; Furman, W. L.; McGregor, L. M.; Hu, S.; Panetta, J. C.; Turner, D.; Fofana, D.; Reddick, W. E.; Leung, W.; Santana, V. M. Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors. Clin. Cancer Res., 2013, 19(1), 236-246.
230. Zhang, P.; Li, H.; Wu, M. L.; Chen, X. Y.; Kong, Q. Y.; Wang, X. W.; Sun, Y.; Wen, S.; Liu, J. c-Myc downregulation: a critical molecular event in resveratrol-induced cell cycle arrest and apoptosis of human medulloblastoma cells. J. Neurooncol., 2006, 80(2), 123-131.
231. Chang, Q.; Chen, Z.; You, J.; McNutt, M. A.; Zhang, T.; Han, Z.; Zhang, X.; Gong, E.; Gu, J. All-trans-retinoic acid induces cell growth arrest in a human medulloblastoma cell line. J. Neurooncol., 2007, 84(3), 263-267.
232. Wang, Q.; Li, H.; Wang, X. W.; Wu, D. C.; Chen, X. Y.; Liu, J. Resveratrol promotes differentiation and induces Fas-independent apoptosis of human medulloblastoma cells. Neurosci. Lett., 2003, 351(2), 83-86.
233. Wei, J. S.; Song, Y. K.; Durinck, S.; Chen, Q. R.; Cheuk, A. T.; Tsang, P.; Zhang, Q.; Thiele, C. J.; Slack, A.; Shohet, J.; Khan, J. The MYCN oncogene is a direct target of miR-34a. Oncogene, 2008, 27(39), 5204-5213
234. Beckers, A.; Van Peer, G.; Carter, D. R.; Mets, E.; Althoff, K.; Cheung, B. B.; Schulte, J. H.; Mestdagh, P.; Vandesompele, J.; Marshall, G. M.; De Preter, K.; Speleman, F. MYCN-targeting miRNAs are predominantly downregulated during MYCNdriven neuroblastoma tumor formation. Oncotarget, 2015, 6(7), 5204-5216.
235. MacDonald, T. J.; Rood, B. R.; Santi, M. R.; Vezina, G.; Bingaman, K.; Cogen, P. H.; Packer, R. J. Advances in the diagnosis, molecular genetics, and treatment of pediatric embryonal CNS tumors. Oncologist., 2003, 8(2), 174-186.
236. Soucek, L.; Evan, G. I. The ups and downs of Myc biology. Curr. Opin. Genet. Dev., 2009, 20(1), 91-95.
237. Felsher, D. W. MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms. Genes Cancer, 2010, 1(6), 597-604
238. Weinstein, I. B.; Joe, A. Oncogene addiction. Cancer Res., 2008, 68(9), 3077-3080; discussion 3080.
239. Prochownik, E. V. c-Myc as a therapeutic target in cancer. Expert Rev. Anticancer Ther., 2004, 4(2), 289-302
240. Wang, H.; Mannava, S.; Grachtchouk, V.; Zhuang, D.; Soengas, M. S.; Gudkov, A. V.; Prochownik, E. V.; Nikiforov, M. A. c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle. Oncogene, 2008, 27(13), 1905-1915.
241. Jain, M.; Arvanitis, C.; Chu, K.; Dewey, W.; Leonhardt, E.; Trinh, M.; Sundberg, C. D.; Bishop, J. M.; Felsher, D. W. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science, 2002, 297(5578), 102-104.
242. Boxer, R. B.; Jang, J. W.; Sintasath, L.; Chodosh, L. A. Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell, 2004, 6(6), 577-586.
243. Pelengaris, S.; Littlewood, T.; Khan, M.; Elia, G.; Evan, G. Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol. Cell, 1999, 3(5), 565-577.
244. Sodir, N. M.; Swigart, L. B.; Karnezis, A. N.; Hanahan, D.; Evan, G. I.; Soucek, L. Endogenous Myc maintains the tumor microenvironment. Genes Dev., 25 (9), 907-916
245. Sodir, N. M.; Evan, G. I. Finding cancer's weakest link. Oncotarget, 2011, 2(12), 1307-1313.
246. Sodir, N. M.; Soucek, L. The Myc world within reach. Methods Mol. Biol., 2013, 1012, 1-6.
247. Wasylishen, A. R.; Penn, L. Z. Myc: the beauty and the beast. Genes Cancer, 1 (6), 532-541
248. Lin, C. H.; Jackson, A. L.; Guo, J.; Linsley, P. S.; Eisenman, R. N. Myc-regulated microRNAs attenuate embryonic stem cell differentiation. Embo J., 2009, 28(20), 3157-3170
249. Wilson, A.; Murphy, M. J.; Oskarsson, T.; Kaloulis, K.; Bettess, M. D.; Oser, G. M.; Pasche, A. C.; Knabenhans, C.; Macdonald, H. R.; Trumpp, A. c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation. Genes Dev., 2004, 18(22), 2747-2763.
250. Soucek, L.; Whitfield, J.; Martins, C. P.; Finch, A. J.; Murphy, D. J.; Sodir, N. M.; Karnezis, A. N.; Swigart, L. B.; Nasi, S.; Evan, G. I. Modelling Myc inhibition as a cancer therapy. Nature, 2008, 455(7213), 679-683.
251. Bettess, M. D.; Dubois, N.; Murphy, M. J.; Dubey, C.; Roger, C.; Robine, S.; Trumpp, A. c-Myc is required for the formation of intestinal crypts but dispensable for homeostasis of the adult intestinal epithelium. Mol. Cell Biol., 2005, 25(17), 7868-7878
252. Muncan, V.; Sansom, O. J.; Tertoolen, L.; Phesse, T. J.; Begthel, H.; Sancho, E.; Cole, A. M.; Gregorieff, A.; de Alboran, I. M.; Clevers, H.; Clarke, A. R. Rapid loss of intestinal crypts upon conditional deletion of the Wnt/Tcf-4 target gene c-Myc. Mol. Cell Biol., 2006, 26(22), 8418-8426.